Relmada Therapeutics, Inc (RLMD)

Etorro trading 970x250
Relmada Therapeutics, Inc (RLMD) Logo

About Relmada Therapeutics, Inc

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York. Address: 880 Third Avenue, New York, NY, United States, 10022

Relmada Therapeutics, Inc News and around…

Latest news about Relmada Therapeutics, Inc (RLMD) common stock and company :

Notable Wednesday Option Activity: BJ, RLMD, DNUT
18 May, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in BJ's Wholesale Club Holdings Inc (BJ), where a total volume of 40,672 contracts has been traded thus far today, a contract volume which is representative of approximately 4.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 237.1% of BJ's average daily trading volume over the past month, of 1.7 million shares..

Look Under The Hood: ESML Has 40% Upside
17 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $46.57 per unit.

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
10 May, 2022 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Relative Strength Alert For Relmada Therapeutics
10 May, 2022 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Noteworthy Monday Option Activity: RLMD, DISH, PUMP
09 May, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Relmada Therapeutics Inc (RLMD), where a total volume of 4,214 contracts has been traded thus far today, a contract volume which is representative of approximately 421,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 166.2% of RLMD's average daily trading volume over the past month, of 253,545 shares..

10 Biggest Price Target Changes For Monday
09 May, 2022 FinancialContent

Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in ...

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
05 May, 2022 Yahoo! Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2022. The Company will host a conference call today, Thursday, May 5, at 4:30 PM Eastern Time/1:30 PM Pacific Time.

Relmada Therapeutics Earnings Preview
04 May, 2022 FinancialContent

Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors ...

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology
29 Apr, 2022 Yahoo! Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today the publication of REL-1017 preclinical data in the peer-reviewed journal, Frontiers in Pharmacology. The article is titled, "REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats," and is available online at: Frontiers | REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MD

Noteworthy Thursday Option Activity: RLMD, GPMT, CARG
28 Apr, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Relmada Therapeutics Inc (RLMD), where a total volume of 4,005 contracts has been traded thus far today, a contract volume which is representative of approximately 400,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 149.9% of RLMD's average daily trading volume over the past month, of 267,160 shares..

Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
28 Apr, 2022 Yahoo! Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2022 after the market close on Thursday, May 5, 2022. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Thursday, May 5, 2022.

Analysts Anticipate 41% Gains Ahead For XPH
11 Apr, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $65.19 per unit.

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
06 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Iovance Plans to File For ...

Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022
04 Apr, 2022 Yahoo! Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company's lead product candidate, will be presented in two poster presentations and one oral presentation at the Ketamine & Related Compounds International Hybrid Conference 2022. The conference is being held Monday, April 4, 2022, through Wednesday, April 6, 2022, in Oxford, United Kingdom, and online.

Here's Why Relmada Therapeutics Shares Are Rising
24 Mar, 2022 FinancialContent

Relmada Therapeutics Inc (NASDAQ: RLMD) shares are trading higher by 7.2% at $25.01 after the company reported better-than-expected ...

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
23 Mar, 2022 Yahoo! Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2021. The Company will host a conference call today, Wednesday, March 23, at 4:30 PM Eastern Time/1:30 PM Pacific Time.

Earnings Scheduled For March 23, 2022
23 Mar, 2022 FinancialContent

Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth ...

Notable Tuesday Option Activity: RLMD, ARCH, Y
22 Mar, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Relmada Therapeutics Inc (RLMD), where a total of 2,580 contracts have traded so far, representing approximately 258,000 underlying shares. That amounts to about 58.7% of RLMD's average daily trading volume over the past month of 439,810 shares..

Relmada Therapeutics's Earnings Outlook
22 Mar, 2022 FinancialContent

Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors ...

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022
16 Mar, 2022 Yahoo! Finance

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021 after the market close on Wednesday, March 23, 2022. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Wednesday, March 23, 2022.

Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events
10 Mar, 2022 Yahoo! Finance

Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in fireside chats at Needham & Company's 1st Annual Neuroscience Forum and Oppenheimer's 32nd Annual Healthcare Conference, taking place March 16th, 2022 at 9:30am ET and March 17th, 2022 at 1:20pm ET, respectively. Please find additional d

Report: Boeing plans steep increase in 737 Max production by end of 2023
09 Mar, 2022 Yahoo! Finance

The target would bring the jet maker close to its output level prior to the global safety grounding that followed two crashes that killed 346 people.

DHL Express Places New Order for Six Additional 777 Freighters
08 Mar, 2022 Yahoo! Finance

DHL Express and Boeing [NYSE: BA] today announced that the world-leading express service provider has placed an order for six additional 777 Freighters. The purchase takes DHL Express' order book total to 28 777 Freighters since it placed its first direct order in 2018 for today's largest and most capable twin-engine freighter.

Can Boeing Soar Again?
08 Mar, 2022 Yahoo! Finance

Covid-19 and Russia have impacted the stock price

Russia's invasion of Ukraine adds to Boeing's widebody worries
07 Mar, 2022 Yahoo! Finance

The company says it has closed its engineering, flight training and customer operations in Moscow as well as a facility in Kyiv, Ukraine, amid war and sanctions. The operations support Boeing's already-troubled 777X and 787 Dreamliner programs.

Report: Boeing planning MAX ramp-up through 2023
07 Mar, 2022 Yahoo! Finance

A reported plan by the Boeing Co. could mean Wichita is less than 24 months away from returning to local output on the 737 MAX not seen since 2019. According to a report from Reuters, which cites two unnamed sources familiar with the plan, Boeing wants to be back at a build rate of 47 aircraft per month on the 737 by the end of 2023. Boeing declined to comment to Reuters and a company spokesperson didn’t immediately respond to the WBJ.

Boeing suspends titanium purchases from Russia
07 Mar, 2022 Yahoo! Finance

The company says it has built up an inventory of the material that will keep the move from hampering production rates.

How companies can put an end to Putin
05 Mar, 2022 Yahoo! Finance

The list of companies standing up to Putin is long and getting longer by the hour.

Ukraine Stance by U.S. Tech Firm Epam Sparks Internal Dissension
02 Mar, 2022 Yahoo! Finance

(Bloomberg) -- Tension over the conflict in Ukraine -- and the role U.S. companies should play in opposing Russia’s invasion -- is playing out within Epam Systems Inc., a Pennsylvania-based company with a large work force in Ukraine. Most Read from BloombergUkraine Update: Russia’s Gas Threat; Cease-Fire Talks StruggleChina Warns U.S. Over Forming Pacific NATO, Backing TaiwanBiden to Sign Crypto Order as Firms Face Sanctions PressureCovid Can Shrink the Brain as Much as a Decade of Aging, Study

Sum Up The Pieces: ESML Could Be Worth $49
01 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $48.55 per unit.

Relmada Therapeutics, Inc (RLMD) is a NASDAQ Common Stock listed in , ,

970x250